Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 194

1.

JAK2 (V617F) mutation is not associated with thrombosis in Behcet syndrome.

Ar MC, Hatemi G, Ekizoğlu S, Bilgen H, Saçli S, Buyru AN, Soysal T, Ülkü B, Yazici H.

Clin Appl Thromb Hemost. 2012 Jul;18(4):421-6. doi: 10.1177/1076029611427440.

PMID:
22203033
2.

The JAK2 V617F mutation and thrombosis.

Austin SK, Lambert JR.

Br J Haematol. 2008 Nov;143(3):307-20. Review. Erratum in: Br J Haematol. 2008 Nov;143(3):451.

PMID:
19004076
3.

Association between thromboembolic events and the JAK2 V617F mutation in myeloproliferative neoplasms.

Takata Y, Seki R, Kanajii T, Nohara M, Koteda S, Kawaguchi K, Nomura K, Nakamura T, Morishige S, Oku E, Osaki K, Hashiguchi E, Mouri F, Yoshimoto K, Nagafuji K, Okamura T.

Kurume Med J. 2014;60(3-4):89-97.

4.

Is the absence of JAK2 mutation a risk factor for bleeding in essential thrombocythemia? An analysis of 106 patients.

Patriarca A, Pompetti F, Malizia R, Iuliani O, Di Marzio I, Spadano A, Dragani A.

Blood Transfus. 2010 Jan;8(1):21-7. doi: 10.2450/2009.0004-09.

5.

JAK2 V617F: implications for thrombosis in myeloproliferative diseases.

Hexner EO.

Curr Opin Hematol. 2007 Sep;14(5):450-4. Review.

PMID:
17934351
6.

Endothelial progenitor cells are clonal and exhibit the JAK2(V617F) mutation in a subset of thrombotic patients with Ph-negative myeloproliferative neoplasms.

Teofili L, Martini M, Iachininoto MG, Capodimonti S, Nuzzolo ER, Torti L, Cenci T, Larocca LM, Leone G.

Blood. 2011 Mar 3;117(9):2700-7. doi: 10.1182/blood-2010-07-297598.

7.

JAK2 (V617F) as an acquired somatic mutation and a secondary genetic event associated with disease progression in familial myeloproliferative disorders.

Rumi E, Passamonti F, Pietra D, Della Porta MG, Arcaini L, Boggi S, Elena C, Boveri E, Pascutto C, Lazzarino M, Cazzola M.

Cancer. 2006 Nov 1;107(9):2206-11.

8.

JAK2 V617F mutation status of 232 patients diagnosed with chronic myeloproliferative neoplasms.

Payzin KB, Savasoglu K, Alacacioglu I, Ozdemirkiran F, Mutlu BB, Bener S, Calli AO, Kucukzeybek BB, Aksun S.

Clin Lymphoma Myeloma Leuk. 2014 Dec;14(6):525-33. doi: 10.1016/j.clml.2014.02.013.

PMID:
24811089
9.

Vascular events in Korean patients with myeloproliferative neoplasms and their relationship to JAK2 mutation.

Bang SM, Lee JS, Ahn JY, Lee JH, Hyun MS, Kim BS, Park MR, Chi HS, Kim HY, Kim HJ, Lee MH, Kim H, Won JH, Yoon HJ, Oh DY, Nam EM, Bae SH, Kim BK; Korean MPN Working Party..

Thromb Haemost. 2009 Mar;101(3):547-51.

PMID:
19277418
10.

Is the JAK2 V617F mutation a hallmark for different forms of thrombosis?

Zerjavic K, Zagradisnik B, Stangler Herodez S, Lokar L, Glaser Krasevac M, Kokalj Vokac N.

Acta Haematol. 2010;124(1):49-56. doi: 10.1159/000314645.

PMID:
20616539
11.

Prevalence of JAK29V617F) mutation in intra-abdominal venous thrombosis.

Deepak A, Punamiya S, Patel N, Parekh S, Mehta S, Shah N.

Trop Gastroenterol. 2011 Oct-Dec;32(4):279-84.

12.

JAK2 V617F mutation in patients with catastrophic intra-abdominal thromboses.

McMahon C, Abu-Elmagd K, Bontempo FA, Kant JA, Swerdlow SH.

Am J Clin Pathol. 2007 May;127(5):736-43.

PMID:
17439832
13.

Prevalence of overt myeloproliferative neoplasms and JAK2 V617F mutation in Korean patients with splanchnic vein thrombosis.

Yoo EH, Jang JH, Park KJ, Gwak GY, Kim HJ, Kim SH, Kim DK.

Int J Lab Hematol. 2011 Oct;33(5):471-6. doi: 10.1111/j.1751-553X.2011.01308.x.

PMID:
21435189
14.

The association of the JAK2 46/1 haplotype with non-splanchnic venous thrombosis.

Zerjavic K, Zagradisnik B, Lokar L, Krasevac MG, Vokac NK.

Thromb Res. 2013 Aug;132(2):e86-93. doi: 10.1016/j.thromres.2013.06.021.

PMID:
23845539
15.

JAK2 V617F mutation prevalence in myeloproliferative neoplasms in Pernambuco, Brazil.

da Silva RR, Domingues Hatzlhofer BL, Machado CG, Lima AS, de Albuquerque DM, dos Santos MN, Fertrin KY, Costa FF, Araújo Ada S, Bezerra MA.

Genet Test Mol Biomarkers. 2012 Jul;16(7):802-5. doi: 10.1089/gtmb.2011.0272.

PMID:
22304488
16.

Identification of oncostatin M as a JAK2 V617F-dependent amplifier of cytokine production and bone marrow remodeling in myeloproliferative neoplasms.

Hoermann G, Cerny-Reiterer S, Herrmann H, Blatt K, Bilban M, Gisslinger H, Gisslinger B, Müllauer L, Kralovics R, Mannhalter C, Valent P, Mayerhofer M.

FASEB J. 2012 Feb;26(2):894-906. doi: 10.1096/fj.11-193078.

PMID:
22051730
17.

The JAK2(V617F) tyrosine kinase mutation identifies clinically latent myeloproliferative disorders in patients presenting with hepatic or portal vein thrombosis.

Goulding C, Uttenthal B, Foroni L, Duke V, Traore A, Kottaridis P, Hoffbrand AV, Patch D, McNamara C.

Int J Lab Hematol. 2008 Oct;30(5):415-9. doi: 10.1111/j.1751-553X.2007.00973.x.

PMID:
19046316
18.

The JAK2 V617F mutation in patients with cerebral venous thrombosis.

Passamonti SM, Biguzzi E, Cazzola M, Franchi F, Gianniello F, Bucciarelli P, Pietra D, Mannucci PM, Martinelli I.

J Thromb Haemost. 2012 Jun;10(6):998-1003. doi: 10.1111/j.1538-7836.2012.04719.x.

19.

Clinical significance of V617F mutation of the JAK2 gene in patients with chronic myeloproliferative disorders.

Basquiera AL, Soria NW, Ryser R, Salguero M, Moiraghi B, Sackmann F, Sturich AG, Borello A, Berretta A, Bonafé M, Barral JM, Palazzo ED, García JJ.

Hematology. 2009 Dec;14(6):323-30. doi: 10.1179/102453309X12473408860226.

PMID:
19941738
20.

Occurrence of the JAK2 V617F mutation in the Budd-Chiari syndrome.

Colaizzo D, Amitrano L, Tiscia GL, Iannaccone L, Gallone A, Grandone E, Guardascione MA, Margaglione M.

Blood Coagul Fibrinolysis. 2008 Jul;19(5):459-62. doi: 10.1097/MBC.0b013e3283049662.

PMID:
18600100

Supplemental Content

Support Center